Nucleus of the soy cluster — the canonical page for what soy does to patient-important
outcomes, whether the feared effects are real, and how the forms differ. Facets (thyroid,
natto/K2-bone, phytate handling) attach here.
The reframe — not “is soy good or bad?” but three fears under symmetric standards
The public question is polarized between soy feminizes men / causes breast cancer and soy is a superfood. Neither pole is the decision. The wiki holds a health axis only and applies the same appraisal bar to the fear and to the boast — a favourable result buys no exemption, an alarming one no free pass. Three fears are separable and each resolves to a direction + magnitude + certainty, not to it’s complicated:
- Hormonal (isoflavones as phytoestrogens -> feminization in men) — refuted, a well-powered null (Reed et al., 2021).
- Breast cancer — neutral-to-protective, and conditional on menopausal status, population and study design (Chen et al., 2014).
- LDL cholesterol — modest lowering via the isolated soy-protein form; the best current intrinsic estimate is ~3% (−4.76 mg/dL) at ~25 g/d (Blanco Mejia et al., 2019), a downward revision of the dated ~13% figure (Anderson et al., 1995). A surrogate — the events benefit is inferred through LDL ApoB and Cumulative Exposure, not measured.
Thyroid (goitrogen) and antinutrient (phytate) fears are named gaps below — not searched here, so neither asserted nor dismissed.
Why the hormonal null is mechanistically expected — isoflavones are SERMs, not estrogen
Isoflavones (genistein, daidzein) have a structure similar to estrogen but preferentially bind and activate ERβ, whereas estrogen has roughly equal affinity for ERα and ERβ; because the two receptors have different tissue distributions and can exert opposite effects, isoflavones act tissue-selectively and are classified as selective estrogen-receptor modulators (SERMs) (Reed et al., 2021). So a naive phytoestrogen = estrogen inference is the wrong model, and the human null below is what the mechanism predicts — mechanism carries directional weight here, but the outcome evidence, not the mechanism, is what settles it (net-effect-not-intended).
Fear 1 — HORMONAL: a genuine null, not “insufficient evidence”
Reed 2021 meta-analyzed the clinical data on whether soy or isoflavone intake moves male reproductive hormones — total testosterone (TT), free testosterone (FT), estradiol (E2), estrone (E1), sex hormone-binding globulin (SHBG): 41 studies; TT and FT measured in 1753 and 752 men, E2 and E1 in 1000 and 239, SHBG in 967 (Reed et al., 2021).
- effect_measure: standardized mean difference (SMD), random-effects. Total testosterone SMD −0.06 (95% CI −0.29 to 0.17; P=0.59; 20 groups, 1241 men, treatment-vs-control); change-over-time 0.09 (−0.02 to 0.20; P=0.12). Free testosterone 0.01 (−0.33 to 0.32; P=0.98). SHBG −0.03 (−0.45 to 0.38; P=0.88). E2 and E1: no significant effect on any model. (Reed et al., 2021)
- population_and_comparator: adult men consuming soyfoods / soy protein (SPI, SPC) / isoflavone extracts, vs control (usually animal protein or usual diet).
- outcome: circulating reproductive hormones — a surrogate, not a patient-important outcome (the feared endpoints are fertility/feminization; hormone levels stand in for them) -> Surrogate Outcomes.
- dose_response_shape: no dose or duration effect — sub-analysis by isoflavone dose (<75 vs ≥75 mg/d) and by study duration (≤12 vs >12 weeks) showed no effect; none of the four ≥12-month studies found an effect on testosterone. (Reed et al., 2021)
- certainty: high for the TT null specifically — n=1753, SMD −0.06 with a tight CI (−0.29 to 0.17) that excludes a meaningful effect, low heterogeneity (I2 30% on the change-over-time model), no funnel-plot publication bias, superseding and confirming a 2010 MA. FT is only moderate: its CI (−0.33 to 0.32) does not exclude a small effect in either direction (n=752 — an imprecise estimate, not a tight null). E1/E2 rest on smaller samples (239/1000). The author’s sweeping summary «neither soy protein nor isoflavone exposure affects TT, FT, E2 or E1 levels in men» is best read as carried by the TT endpoint (Reed et al., 2021).
This is a null, not a gap — most firmly for testosterone. Apply the expectancy test: if soy lowered testosterone, a 41-study MA measuring TT in 1753 men, powered to detect it, would have. It did not, across every model, dose, and duration — that is evidence of no meaningful effect on the endpoint the feminization fear is actually about, one of the four evidence states, not unproven. The estradiol/estrone arms are consistent with no effect but less tightly bounded. The feared cases (gynecomastia, hypogonadism) involved intakes near 360 mg/d isoflavones, roughly nine times a typical native-Japanese intake (~30-50 mg/d) — outside the range achievable from foods (Reed et al., 2021).
Provenance caveat (symmetric standards): the corresponding author (Messina) and one co-author work in soy-industry-adjacent nutrition consultancy. The null is nonetheless robust — low heterogeneity, no funnel-plot asymmetry, a pre-existing 2010 MA reaching the same result, and it runs toward the direction a SERM mechanism predicts — so the finding is not carried by the framing. But the source is flagged, not exempt.
Fear 2 — BREAST CANCER: neutral-to-protective, conditional, and study-design-confounded
Chen 2014 pooled 35 epidemiological studies (odds ratios, high-vs-low isoflavone intake), stratified by menopausal status and study region/design (Chen et al., 2014).
| Stratum | Premenopausal OR (95% CI) | Postmenopausal OR (95% CI) |
|---|---|---|
| Summary | 0.74 (0.64–0.85) | 0.75 (0.63–0.86) |
| Asian countries | 0.59 (0.48–0.69) | 0.59 (0.44–0.74) |
| Western countries | 0.90 (0.77–1.04), NS | 0.92 (0.83–1.00), marginal |
- The pooled protection is carried by the weaker designs (read this before the headline number). The summary OR ~0.75 is confounded by study design: prospective cohort / nested case-control studies — the stronger designs — showed no significant protection (premenopausal cohorts OR 0.94, 0.74–1.14; postmenopausal cohorts 0.86, 0.73–1.00 — borderline, upper bound touching the null), while the inverse association came from retrospective case-control studies, whose recall and selection biases systematically inflate a diet-disease association. So the ~25% reduction is a case-control-driven figure, not a cohort-confirmed one. This is a weaker-design inflates the favourable arm pattern (a cousin of the artifact-arm problem on The U-Shaped Association Artifact, though the mechanism here is recall/selection bias, not unequal reporting precision). (Chen et al., 2014)
- Direction: inverse (protective) or neutral — never a raised risk in any stratum.
- Population-conditional: in Western women (pre- or post-menopausal) the marginal Western signal vanished once stratified by design — Chen concludes there is no evidence of an association in Western women, attributing the Asian protection to early-life and higher lifelong intake rather than to adult supplementation. Transportability caveat: the protective estimate is an Asian / lifelong-exposure finding, not a promise for a Western adult adding soy.
- certainty: low-to-moderate — observational, heterogeneous (I2 up to 84%), publication bias detected (Egger), and the strongest designs are null. The defensible claim is “not a risk, and plausibly protective under lifelong high intake,” not “soy prevents breast cancer.”
Fear 3 — LDL CHOLESTEROL: modest lowering, baseline-dependent, via isolated soy protein
Anderson 1995 — the landmark MA of 38 controlled trials substituting soy protein (mean 47 g/d) for animal protein (Anderson et al., 1995):
- effect_measure (absolute, net vs control diet): total cholesterol −23.2 mg/dL (−9.3%); LDL −21.7 mg/dL (−12.9%); triglycerides −13.3 mg/dL (−10.5%); HDL non-significant (+2.4%). (Anderson et al., 1995)
- dose_response_shape: the soy-diet-alone model estimated 25 / 50 / 75 g/d -> cholesterol decreases of 8.9 / 17.4 / 26.3 mg/dL — roughly monotone over the studied range, no knee located. (Anderson et al., 1995)
- effect_modifiers: baseline risk (route (a)) dominates — initial cholesterol accounted for ~77% of between-study variance. Normal (<200 mg/dL): non-significant −3.3%; severe hypercholesterolemia (>335 mg/dL): −19.6%. The lever is real mainly for people who already have high cholesterol. (Anderson et al., 1995)
- population_and_comparator: isolated or textured soy protein replacing animal protein — whole soybeans were excluded from the analysis. This is the specify-the-exposure catch: the LDL evidence is for the isolated-protein form, not for tofu/edamame, and not for soy sauce -> Is the Food Category Doing Any Work.
- outcome: LDL/total cholesterol — a surrogate for ASCVD; its causal transmission to events is the LDL ApoB and Cumulative Exposure claim, not assumed here.
The magnitude is revised DOWN — Blanco Mejia 2019 (type-F refinement of the Anderson leg)
Blanco Mejia 2019 re-pooled the 46 soy-protein RCTs the FDA compiled to decide whether to revoke the soy heart-health claim (43 with data; 41 for LDL / 50 comparisons, 43 for TC / 52 comparisons; 2607 participants). At a median dose of 25 g/d over a median 6 wk, soy protein (79% isolated, vs mostly dairy-protein controls) lowered:
- LDL by −4.76 mg/dL (−0.12 mmol/L); 95% CI −6.71, −2.80; = −3.2% (95% CI −4.5, −1.9%); I2=55%, no publication bias, no subgroup effect modification, and no dose-response or threshold located (the studied dose range was narrow) (Blanco Mejia et al., 2019).
- TC by −6.41 mg/dL (−0.17 mmol/L); 95% CI −9.30, −3.52; = −2.8% (95% CI −4.1, −1.5%); I2=74% (Blanco Mejia et al., 2019).
- The abstract states the effect as «approximately 3-4%» LDL lowering (Blanco Mejia et al., 2019).
This is F (claim-refinement), not E (independent backing): both are meta-analyses pooling soy-protein RCTs on the same surrogate, over an overlapping trial pool (Blanco cites Anderson as ref 70 and compares directly), so they are the same route re-estimated, not two independent routes converging — no confidence bump is bought by their agreement.
Parameter table — why the two magnitudes differ (BLOCKING before the comparison prose):
| Parameter | Blanco Mejia 2019 (chunk 01) | Anderson 1995 (chunk 01) | Same quantity? |
|---|---|---|---|
| LDL net change vs control | −4.76 mg/dL (−0.12 mmol/L); −3.2% | −21.7 mg/dL (0.56 mmol/L); −12.9% | Same measure (net between-group MD on LDL, matched-protein control), but NO on the overall figure — confounded by dose + baseline (below) |
| TC net change vs control | −6.41 mg/dL (−0.17 mmol/L); −2.8% | −23.2 mg/dL (0.60 mmol/L); −9.3% | same measure; differs by dose + baseline |
| Soy dose | median 25 g/d (IQR 23.8, 38.1) | mean 47 g/d (range 17-124) | NO — Anderson ~2x the dose |
| Baseline population | LDL 110-201 mg/dL, mean 147.6 (borderline) | wide, incl. severe hypercholesterolemia (>335); baseline drove ~77% of variance | NO — Anderson spans much higher (more responsive) baselines |
| Comparator | non-soy protein (72% dairy) | animal protein, fat/SFA/cholesterol-matched in most | ~yes (both matched-protein = “intrinsic”) |
| Exposure form | 79% ISP + soy foods/milk | isolated/textured SP; whole soybeans excluded | ~yes (predominantly isolated protein) |
Reconciliation. The overall Anderson −12.9% and Blanco −3.2% are not the same quantity: Anderson pooled both higher doses and higher-baseline populations, and both inflate the effect (dose-response + the route-(a) baseline dependence Anderson itself found). Matched at Blanco’s population, the gap largely closes — Anderson’s own normal-baseline (<200 mg/dL) quartile was NS −3.3% cholesterol (LDL Q1 −7.7%), and its 25 g/d dose-model point was −8.9 mg/dL TC (vs Blanco’s −6.41). So the downward revision is partly a genuine update (a cleaner FDA-identified set, no detectable dose-response) and partly explained by lower dose + lower baseline, not a contradiction (Anderson et al., 1995; inferred from Blanco Mejia et al., 2019). Both MAs agree on direction and on baseline-amplification.
Intrinsic vs extrinsic (a decision-relevant distinction, type-B). Blanco’s pooled effect is the
intrinsic effect (soy vs a matched-protein control). The real-world effect adds an extrinsic /
displacement component when soy replaces saturated-fat-rich animal protein — «The overall effect
in real life could be potentially higher than that seen in these trials» — an NHANES-III estimate put
the displacement advantage of 25 g/d soy for animal protein at ~4.3% additional LDL lowering
(Blanco Mejia et al., 2019). So the trial figure is a floor
for a substitution framing (layer-3), not the ceiling.
Surrogate bounding (the sharp point). LDL/TC are surrogates — Blanco reports no hard cardiovascular outcomes, calling them «surrogates of CVD». The events benefit of a −0.12 mmol/L LDL reduction is inferred through the cumulative-exposure causality on LDL ApoB and Cumulative Exposure, never measured here — and in absolute terms 0.12 mmol/L is a small LDL move beside a standard drug lever (a statin lowers LDL ~1.5-2 mmol/L), so soy protein sizes as a small, non-substitutable-for-a-drug lever on this outcome (layer-1). The intrinsic effect is real, directionally certain, and modest.
Mechanism (proposed, not established). Blanco attributes the intrinsic effect to the 7S globulin
fraction of soy protein (shared with other legumes), which «appears to inhibit hepatic Apo B
synthesis»; isoflavones are judged a «less likely» contributor to the lipid effect
(Blanco Mejia et al., 2019) [EXTRACTED — asserted]. This
is a mechanistic proposal with directional weight, not an outcome finding.
Two live caveats (symmetric standards):
- The 1995 magnitude is superseded. Anderson’s ~13% LDL figure was DATED and industry-funded (Protein Technologies International, lead author on its advisory group); treat Blanco Mejia’s ~3% intrinsic effect at ~25 g/d as the current estimate, holding Anderson for the baseline-dependence and dose structure it still supplies. Blanco is itself soy/food-industry-entangled (co-author Messina directs the Soy Nutrition Institute) — but it runs against sponsor interest by shrinking the claim, on a gold FDA-identified set with no funnel-plot asymmetry, so the direction is not carried by the framing. Both favourable-industry results get more scrutiny, not less (Blanco Mejia et al., 2019).
- The mechanism was not established in either MA; Anderson notes primate data attributing 60–70% of the effect to soy estrogens (isoflavones), but this is animal-derived and speculative, and Blanco judges the isoflavone route the less likely one (Anderson et al., 1995).
The forms are NOT interchangeable — specify the exposure
“Soy” names several different exposures with different active fractions and different evidence
(a terminological disambiguation with decision consequences, type-B):
- Isolated / textured soy protein — the LDL-lowering form (Anderson’s exposure); high-DIAAS complete plant protein -> Protein Quality and the DIAAS Score.
- Whole / minimally processed (tofu, edamame, soy milk) — the isoflavone + complete-protein workhorse; carries the hormone/cancer evidence (foods, not isolates).
- Fermented (miso, tempeh, natto) — lower phytate (fermentation defuses the antinutrient concern -> Antinutrients in Plant Foods); natto is a notably rich dietary source of vitamin K2 (MK-7) (a widely-reported compositional fact; whether the MK-7 moves a bone or vascular outcome is the GAP below). Cross-links Fermented Foods for the live-culture question, but the soy matrix lives here.
- Soy sauce / tamari — a condiment and salt vehicle with negligible isoflavone dose; do not credit it with soy’s effects. A specify-the-exposure catch.
Synthesis — soy’s evidence is unusually FORM-dependent
Placing the three MAs side by side yields a move present in no single source (type-A): each fear was
tested with a different soy exposure — Reed pooled soyfoods + isolates + isoflavone extracts on
hormones, Chen pooled dietary-isoflavone epidemiology on cancer, Anderson isolated only the isolated
soy-protein form on lipids and excluded whole soybeans. So the composite answer is not “soy does X”
but a form-indexed one: the isolated protein moves LDL, the isoflavone-bearing foods leave male
hormones unmoved and sit neutral-to-protective on breast cancer, and the condiment does nothing. This
is Is the Food Category Doing Any Work instantiated — the category “soy” is too coarse to carry a
single verdict, and the better-designed evidence tracks the better-specified exposure.
The three sources answer three different outcomes (hormones · cancer · lipids), so they are
facets of this nucleus, not a tension — no joined issue, no forced independent-backing claim. The
lipids outcome now rests on two MAs, but F-related (Blanco Mejia refines Anderson’s magnitude on
an overlapping trial pool — not independent E), so confidence stays medium overall (four gold-tier
MAs, but each outcome effectively single-route, and the LDL/TC endpoints are surrogates).
One axis only
This page holds a health axis. Soy also carries environmental (low-footprint protein) and economic loads and is entangled with the animal-feed / deforestation debate; the wiki records only that those trade-offs exist and does not price them against the health finding.
Facets held elsewhere
- Cognition (a fourth outcome) — HELD. Supplemental soy isoflavones produce a small, memory-carried benefit on neuropsychological test scores; the earlier tofu-harm scare does not survive confounding scrutiny; and the observational isoflavone-cognition signal is null. The full appraisal — the Cui 2020 RCT MA effect estimates, the tofu-harm rebuttal, and why the RCT/observational split is a distinction rather than a tension — lives on Soy Isoflavones and Cognitive Function. The ERβ-SERM mechanism above is the same one invoked there for the memory-domain specificity.
Gaps and held threads
- LDL magnitude — CASHED (Blanco Mejia 2019 held). The intrinsic effect is ~3% (−4.76 mg/dL) at
~25 g/d, revising Anderson’s ~13% downward; see Fear 3. Remaining LDL gap: no hard CVD-outcome
trial of soy protein — the events benefit stays inferred through LDL ApoB and Cumulative Exposure.
G (needs a soy -> ASCVD-events trial, which does not exist). - Thyroid (goitrogen) — GAP, not searched. Prior (to test, not asserted): mild goitrogen only
under iodine deficiency; in euthyroid, iodine-replete people likely no clinically important harm
(may modestly raise levothyroxine dose needs — an absorption/timing issue).
AWAITS a soy-thyroid SR/MA conditioned on iodine status. - Antinutrient / phytate — the mineral-binding concern is handled at Antinutrients in Plant Foods (reduced by fermentation/soaking; a marginal-mineral-status issue, not a general harm); no soy-specific outcome evidence extracted here.
- Natto / vitamin K2 (MK-7) -> bone and vascular calcification — GAP.
AWAITS a natto/MK-7 bone or CVD outcome SR/MA(cross-links Fermented Foods). - Prostate cancer, menopausal symptoms, bone density — named in the deliverable scope, no source held. GAP.
- Soy in ER-positive breast-cancer survivors (the genistein / tamoxifen-interaction fear) — a
prominent clinical worry that dietary isoflavones might stimulate estrogen-receptor-positive tumour
growth or blunt tamoxifen. Not adjudicated here (Chen covers incidence, not survivors). GAP.
AWAITS a soy-and-breast-cancer-survival / isoflavone-tamoxifen SR. - Absolute breast-cancer risk reduction — Chen reports relative ORs only; the absolute benefit
depends on baseline incidence in the stratum, which the MA does not supply.
G (needs aggregation).